Open Horizon Scientific Review

Vol. 02 No.04 2024

Molecular Mechanisms of Enzyme Inhibition by Emerging Chemical Compounds

Ayesha Noreen Siddiqui

Department of Biochemistry, Quaid-i-Azam University, Islamabad, Pakistan

ABSTRACT

Enzyme inhibition is one of the most productive strategies in drug discovery, agrochemistry and chemical biology, and it is being reshaped by new classes of chemical compounds that act through unconventional mechanisms. This article reviews the molecular principles by which small molecules suppress enzyme activity and examines how emerging compounds extend these principles. Classical reversible modes, including competitive, noncompetitive and uncompetitive inhibition, are described together with irreversible and covalent mechanisms, allosteric modulation and time-dependent binding. Newer chemotypes such as targeted covalent inhibitors, fragment-derived leads, macrocycles and degrader molecules that remove enzymes rather than merely blocking them are then discussed. Structural, biophysical and computational methods used to decipher binding mechanisms are summarized, and the challenges of resistance, selectivity and toxicity are considered. The review argues that a detailed mechanistic understanding, rather than potency alone, should guide the design and optimization of next-generation inhibitors.

Key words: *enzyme inhibition, covalent inhibitors, allosteric modulation, targeted protein degradation, structure-based drug design*

Introduction:

Enzymes catalyze nearly every reaction of cellular metabolism, signaling and gene expression, and their dysregulation underlies cancer, infection, metabolic disorders and neurodegeneration. Small molecules that selectively inhibit enzymes therefore form a large share of approved medicines and a significant portion of herbicides, insecticides and research probes. Understanding exactly how an inhibitor interacts with its target, and not only how strongly, determines its selectivity, duration of action, susceptibility to resistance and safety profile (Copeland, 2013; Robertson, 2005).

Over the past two decades the chemical space of inhibitors has broadened considerably. Alongside traditional substrate mimics and transition-state analogues, researchers now exploit covalent warheads tuned for selective reactivity, fragments that bind weakly but efficiently, macrocyclic scaffolds that engage large surfaces, and bifunctional molecules that recruit cellular degradation machinery. These emerging compounds challenge simple

kinetic classifications and demand integrated mechanistic analysis combining kinetics, structure and computation.

This article provides a structured overview of the molecular mechanisms of enzyme inhibition. It starts from the kinetic framework, moves through the principal binding modes and the newest compound classes, reviews the methods used to establish mechanism, and concludes with the practical challenges that limit translation into effective and safe agents.

1. Fundamentals of Enzyme Kinetics and Inhibition

The behavior of most enzymes can be described by Michaelis-Menten kinetics, in which the reaction rate depends on the substrate concentration through two parameters: the maximum velocity, which reflects catalytic capacity, and the Michaelis constant, which reflects the substrate concentration needed to reach half of that velocity. An inhibitor alters one or both of these apparent parameters, and the pattern of change provides the first clue to its mechanism. Potency is commonly reported as the half-maximal inhibitory concentration, but this value depends on assay conditions such as substrate level, and it is converted to an inhibition constant through relationships such as the Cheng-Prusoff equation to permit meaningful comparison (Cheng & Prusoff, 1973).

Beyond equilibrium measures, modern practice emphasizes the kinetics of binding itself. The association and dissociation rate constants define how quickly an inhibitor engages its target and how long it remains bound. A long residence time can sustain pharmacological effect after free drug has been cleared, and in many cases correlates better with cellular and in vivo efficacy than affinity alone (Holdgate et al., 2018). Mechanistic enzymology thus examines not only whether an inhibitor works but also how binding unfolds in time.

2. Reversible Inhibition Modes and Their Kinetic Signatures

Reversible inhibitors associate with an enzyme through noncovalent forces such as hydrogen bonds, electrostatic interactions, hydrophobic contacts and van der Waals forces, and they can dissociate freely. In competitive inhibition the compound occupies the substrate site or overlaps with it, so substrate and inhibitor compete for the same enzyme form. High substrate concentration can overcome the effect, which appears as an increase in the apparent Michaelis constant with no change in maximum velocity.

Noncompetitive inhibitors bind at a different site and reduce the catalytic turnover of the enzyme whether or not

substrate is present, lowering the apparent maximum velocity without altering substrate affinity. Uncompetitive inhibitors bind only to the enzyme-substrate complex, so that both apparent parameters decrease together. Mixed inhibition describes cases in which the inhibitor binds both free enzyme and the complex with unequal affinity. These patterns are visualized in double-reciprocal and direct plots and remain essential diagnostic tools, although they should be confirmed by structural evidence because different binding sites can produce similar kinetic outcomes (Copeland, 2013).

3. Irreversible and Covalent Inhibition

Irreversible inhibitors form a stable covalent bond with a catalytic or nearby residue, permanently inactivating the enzyme until new protein is synthesized. Classical examples include aspirin, which acetylates a serine residue of cyclooxygenase, and beta-lactam antibiotics, which acylate bacterial transpeptidases. The mechanism generally proceeds in two steps: initial reversible recognition of the compound by the active site, followed by chemical bond formation with a reactive group termed the warhead. The overall efficiency is therefore described by the ratio of the inactivation rate to the inhibition constant rather than by a single equilibrium value.

Covalent drugs were long regarded with caution because of concerns over off-target reactivity and immune responses, yet a careful analysis showed that many successful medicines act in this way (Singh et al., 2011). Contemporary design builds on this insight by pairing a highly selective reversible scaffold with a mild electrophile, such as an acrylamide, that reacts only when properly positioned near the target nucleophile. Reversible covalent warheads, including nitriles and boronic acids, offer prolonged engagement while permitting turnover of the adduct and reducing permanent protein modification.

4. Allosteric Modulation and Conformational Control

Allosteric inhibitors bind at sites remote from the active center and alter enzyme function by changing conformational equilibria or dynamics. Rather than blocking substrate access directly, they stabilize inactive states, disrupt coupling between domains or restrict motions required for catalysis. Because allosteric sites are generally less conserved than active sites among related enzymes, such compounds can achieve exceptional selectivity, which is particularly valuable for protein kinases, phosphatases and proteases where active sites are highly similar (Nussinov & Tsai, 2013).A striking illustration is the discovery of compounds that bind a

cryptic pocket in a mutant form of the small GTPase K-Ras and trap it in an inactive conformation, thereby addressing a target once considered undruggable (Ostrem et al., 2013). Allosteric mechanisms also include positive modulation, in which a compound enhances activity, and they can generate effects that are saturable, so that increasing the dose beyond a ceiling does not produce further inhibition. This property may improve safety but complicates dose selection and the interpretation of standard potency assays.

5. Emerging Compound Classes: Covalent Probes, Fragments and Macrocycles

Several compound classes are expanding the reach of enzyme inhibition. Targeted covalent inhibitors discovered through chemoproteomic screening identify reactive cysteine, lysine and tyrosine residues across the proteome and enable the development of probes for enzymes lacking well-defined pockets. Fragment-based discovery starts from very small molecules that bind weakly but with high ligand efficiency; structural information is then used to grow, link or merge fragments into potent leads. Since its emergence the approach has produced several clinical candidates and approved drugs, and it has proved especially useful for difficult targets (Erlanson et al., 2016).

Macrocyclic compounds, including cyclic peptides and natural-product-like scaffolds, occupy a chemical space between small molecules and biologics. Their constrained conformations reduce the entropic penalty of binding and permit contact with extended or shallow surfaces, enabling inhibition of enzymes whose active sites are broad or solvent exposed. Metal-containing complexes, photoswitchable inhibitors that allow light-controlled activity, and natural products from plants and microorganisms add further mechanistic diversity. Together these classes illustrate that inhibition can arise from induced fit, conformational selection, covalent capture or interference with protein-protein interactions that regulate catalysis.

6. Targeted Degradation by Proteolysis-Targeting Chimeras and Molecular Glues

A conceptual shift in enzyme control is provided by compounds that eliminate the target protein instead of occupying it. Proteolysis-targeting chimeras are bifunctional molecules composed of a ligand for the target enzyme, a ligand for an E3 ubiquitin ligase and a connecting linker. By forming a ternary complex, they bring the enzyme close to the ligase machinery, trigger ubiquitination and direct the protein to the proteasome for degradation. The first such molecules

were reported at the beginning of the century, and later small-molecule versions showed efficient intracellular knockdown at low concentrations (Sakamoto et al., 2001; Bondeson et al., 2015).

Because one degrader molecule can act catalytically on many copies of the target, activity does not require sustained occupancy, and even weak binders may achieve strong effects. Molecular glues operate through a related principle: the immunomodulatory drug thalidomide and its analogues bind the ligase substrate receptor cereblon and reshape its surface so that new protein substrates are recruited and degraded (Fischer et al., 2014). Mechanistic analysis of these compounds focuses on ternary complex stability, cooperativity and linker geometry, which differ fundamentally from the classical affinity-driven paradigm.

7. Structural and Biophysical Methods for Mechanistic Elucidation

Establishing how an inhibitor works requires converging evidence from several techniques. X-ray crystallography provides atomic-resolution views of inhibitor-enzyme complexes and has long been central to structure-based design, while cryo-electron microscopy now resolves large assemblies, membrane enzymes and ternary degrader complexes that resist crystallization. Nuclear magnetic resonance spectroscopy detects weak fragment binding, maps interaction surfaces and reports on protein dynamics in solution.

Biophysical methods quantify the thermodynamics and kinetics of binding. Isothermal titration calorimetry measures binding enthalpy and stoichiometry, surface plasmon resonance resolves association and dissociation rates, and differential scanning fluorimetry detects ligand-induced stabilization. For covalent inhibitors, intact-protein and peptide mass spectrometry confirm the site and extent of modification, while time-resolved kinetic assays determine inactivation parameters. Hydrogen-deuterium exchange and single-molecule approaches reveal how inhibitors perturb conformational ensembles, which is vital for understanding allosteric mechanisms (Holdgate et al., 2018).

8. Computational Modeling and Machine Learning Approaches

Computational methods complement experiments by providing atomic-level hypotheses and by screening vast numbers of candidate molecules. Molecular docking predicts binding poses and ranks compounds, while molecular dynamics simulations reveal the flexibility of enzyme-inhibitor complexes, the opening of cryptic pockets and the pathways by which ligands enter and leave binding sites. Free energy calculations estimate


relative affinities with increasing accuracy, and quantum mechanical and hybrid approaches model bond formation in covalent inhibition and the reaction coordinate of transition-state analogues.

Machine learning is accelerating these efforts. Deep learning systems for structure prediction have made reliable models available for most proteins, extending structure-based design to targets without experimental structures (Jumper et al., 2021). Generative models propose novel scaffolds with desired properties, and predictive models estimate selectivity, solubility and toxicity early in the design cycle. These tools remain limited by data quality, bias toward well-studied targets and difficulty in representing dynamic and covalent processes, and their predictions must therefore be validated experimentally.

9. Resistance, Selectivity and Toxicity Challenges

Despite their promise, enzyme inhibitors face persistent obstacles. Resistance arises when mutations alter the binding site, enhance expression of the target or activate bypass pathways. Covalent inhibitors can lose activity when the reactive residue is replaced, while allosteric compounds may be defeated by mutations that shift conformational equilibria. Degraders can be compromised by loss or mutation of the recruited ligase. Designing compounds that exploit conserved catalytic features, that act through multiple mechanisms or that are used in combination can delay the emergence of resistance.

Selectivity and safety are equally important. Inhibitors may bind related enzymes, generating adverse effects, and reactive compounds may modify unintended proteins or form toxic metabolites. Proteome-wide profiling, counter-screening against related enzymes and early assessment of metabolic liability help to identify problems before clinical development. Practical issues such as membrane permeability, oral bioavailability and the large size of bifunctional degraders also limit translation. Addressing these constraints will require mechanistic insight, careful pharmacokinetic optimization and rigorous experimental validation (Robertson, 2005).



Summary

Enzyme inhibition spans a continuum of mechanisms, from simple competition for the active site to covalent modification, allosteric control and targeted degradation. Kinetic analysis provides the foundation for classifying inhibitors, but binding rates, residence time, conformational effects and cellular context are equally important in determining biological outcome. Emerging compound classes, including targeted covalent inhibitors, fragment-derived leads, macrocycles and degraders, expand the range of enzymes that can be modulated and allow strategies that were not possible with conventional occupancy-based drugs. Structural biology, biophysics and computational modeling now work together to reveal how these compounds act. Continued attention to resistance, selectivity and pharmacokinetics will determine how effectively mechanistic knowledge is converted into safe and durable therapeutic and agrochemical agents.

References:

- Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., et al. (2015). Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature Chemical Biology, 11(8), 611–617.
- Cheng, Y., & Prusoff, W. H. (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology, 22(23), 3099–3108.
- Copeland, R. A. (2013). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (2nd ed.). Wiley.
- Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016). Twenty years on: the impact of fragments on drug discovery. Nature Reviews Drug Discovery, 15(9), 605–619.
- Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., et al. (2014). Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide. Nature, 512(7512), 49–53.
- Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018). Mechanistic enzymology in drug discovery: a fresh perspective. Nature Reviews Drug Discovery, 17(2), 115–132.
- Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589.
- Nussinov, R., & Tsai, C.-J. (2013). Allostery in disease and in drug discovery. Cell, 153(2), 293–305.
- Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013). K-Ras(G12C) inhibitors

allosterically control GTP affinity and effector interactions. Nature, 503(7477), 548–551.

- Robertson, J. G. (2005). Mechanistic basis of enzyme-targeted drugs. Biochemistry, 44(15), 5561–5571.
- Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001). Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences, 98(15), 8554–8559.
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011). The resurgence of covalent drugs. Nature Reviews Drug Discovery, 10(4), 307–317.